The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1093 Ozempic articles
Boston Mayor Michelle Wu announced a deal with unions to implement prior authorization for GLP-1 weight loss drugs like Ozempic and Wegovy, saving the city $10.6 million. This move addresses skyrocketing health costs that threatened 22.6% premium hikes. City workers must now get approval for coverage on these popular obesity treatments.
Amid the GLP-1 boom driving med-spas and weight loss clinics, VITL has landed $7.5M in Series A funding to revolutionize e-prescribing for cash-pay providers. The platform slashes prescription times to seconds with real-time pricing and tracking from compounding pharmacies. With 630 clinics onboard and eight-figure ARR, VITL is poised to scale in the growing peptide and aesthetic market.
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
GLP-1 medications are suppressing appetite, prompting users to prioritize protein quality over quantity—and dairy is ideally positioned to meet this demand, says Valio's innovation chief Dr. Kevin Deegan. At the Arena Dairy Innovation Strategies conference, experts discussed how these drugs change consumer perceptions of protein and sweetness. While some users revert to old habits post-treatment, dairy's natural, high-quality proteins offer a strategic advantage.
Lawsuits against Ozempic manufacturer Novo Nordisk are exploding in the US, with patients alleging the company hid severe side effects like gastroparesis and sudden vision loss from semaglutide. Originally a type 2 diabetes drug, Ozempic's popularity as a weight loss shot has sparked debates on safety and marketing. Despite high demand, experts urge medical supervision to avoid serious risks.
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
